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1684-1182/Copyright ª 2014, TaiwanBackground/Purpose: This study investigated the correlation between antibiotic consumption
and the incidence of health care-associated infections (HCAIs) caused by imipenem-resistant
Acinetobacter baumannii (IRAB) at a hospital in Taiwan from 2005 to 2010.
Methods: Data on annual consumption (defined daily dose per 1000 patient-days) of extended-
spectrum cephalosporins, b-lactam-b-lactamase inhibitor combinations, carbapenems, amino-
glycosides, and fluoroquinolones from 2005 to 2010 were analyzed. Yearly aggregated data on
the number of nonduplicate clinical IRAB isolates causing HCAI were collected. The incidence
rates of HCAI caused by IRAB were defined as the number of patients infected with IRAB per
1000 inpatient-days.
Results: The trend of total consumption (defined daily dose per 1000 patient-days) of
extended-spectrum cephalosporins, carbapenems, and fluoroquinolones was significantly
increased, but the use of aminoglycosides decreased during 2005 to 2010. During the same
period, the incidence of HCAI caused by IRAB gradually increased. The consumptions of carba-
penems and fluoroquinolones were positively correlated with the incidence of HCAI caused byof Intensive Care Medicine, Chi Mei Medical Center, Liouying, Number 201, Taikang, Taikang Village,
an.
il.com (W.-L. Liu).
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Antibiotic consumption and resistance 541IRAB. There was no significant association between the use of extended-spectrum cephalospo-
rins, b-lactam-b-lactamase inhibitor combinations, and aminoglycosides and the incidence of
HCAI caused by IRAB.
Conclusion: The increasing use of carbapenems and fluoroquinolones was associated with the
increasing incidence of HCAI caused by IRAB.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The incidence of health care-associated infection (HCAI)
caused by Gram-negative bacteria, particularly multidrug-
resistant bacteria, has gradually increased and exerted a
global impact on public health.1e8 Moreover, infections
caused by resistant microorganisms would lead to many
adverse outcomes, including extended length of stay,
higher health care costs, and greater hospital morbidity and
mortality.3,5 Acinetobacter baumannii has recently
emerged as a major pathogen causing HCAI and is notorious
for its capacity to rapidly accumulate mechanisms of anti-
biotics resistance.9 Multidrug-resistant A. baumannii can
cause various types of HCAI, including bacteremia, pneu-
monia, meningitis, urinary tract infection, and wound in-
fections.9,10 Prior use of broad-spectrum antibiotics was
demonstrated to be a major risk factor for acquiring
multidrug-resistant A. baumannii infections.10,11
Although several studies have investigated the rela-
tionship between antibiotic consumption and antibiotic
resistance, the inconsistent results among these studies
may be attributable to differences in resistance profiles
and antibiotic prescribing practices in different
countries.12e18 These findings support the necessity of
monitoring aggregate antibacterial drug use at local and
national levels in order to evaluate the associations be-
tween the use of antibiotics and emerging antibiotic re-
sistances. This study investigated the correlations between
antibiotic consumption and incidence of HCAI caused by
IRAB from 2005 to 2010 at a hospital in southern Taiwan.Materials and methods
Setting
Chi Mei Medical Center, Liouying branch, is an 800-bed
hospital that started to provide primary and tertiary care in
southern Taiwan in 2005. The number of annual patient-
days at the hospital significantly increased from 169,886 in
2005 to 256,563 in 2010 (p < 0.002). Yearly aggregated data
on the number of nonduplicate clinical carbapenem-
resistant A. baumannii (CRAB) isolates causing HCAI were
collected. HCAI was defined according to the National
Nosocomial Infection Surveillance guidelines.19 The inci-
dence rates of HCAI caused by IRAB were defined as the
number of patients with HCAI caused by IRAB per 1000
inpatient-days. In our hospital, all attending physicians are
not allowed to prescribe antimicrobial agents, including at
least second-generation cephalosporins, b-lactam-b-lactamase inhibitor combinations, carbapenems (imipe-
nem, meropenem, and ertapenem), and fluoroquinolones,
without the permission of the infection disease specialists.
Antibiotic agents and consumption
Data on annual consumption (defined daily dose per 1000
patient-days) of extended-spectrum cephalosporins (ceftri-
axone, flomoxef, ceftazidime, and cefpirome), b-lactam-b-
lactamase inhibitor combinations (piperacillinetazobactam),
carbapenems (imipenem, meropenem, and ertapenem),
aminoglycosides (amikacin and gentamicin), sulbactam, and
fluoroquinolones (ciprofloxacin, moxifloxacin, and levo-
floxacin) from 2005 to 2010 were obtained from the pharmacy
department of the hospital. Levofloxacin and ertapenem
were introduced into our hospital in 2007.
Bacterial isolates
A. baumannii isolates were identified using conventional
biochemical tests as well as two commercial identification
kits, Api20NE (bioMerieux) and the Phoenix System (Becton
Dickinson, Sparks, MD, USA). Disk diffusion methods were
applied for antibiotic susceptibility tests. Isolates were
classified as susceptible or resistant (including intermediate
category) according to Clinical and Laboratory Standards
Institute guidelines.20e22
Statistical analysis
Linear regression analysis was used to analyze the trend in
annual patient-days, annual consumption of antibiotic
agents, and the trend in the imipenem resistant rate of A.
baumannii causing all HCAI with time. Pearson’s correlation
coefficient was used to determine the relationship between
annual antibiotic consumption and trends in incidence of
HCAI caused by IRAB. A p value <0.05 was considered sta-
tistically significant.
Results
Annual antibiotic consumption
In general, the usage of each antibiotic agent varied with
years (Fig. 1). Fluoroquinolones were the most commonly
used antibiotics, followed by extended-spectrum cephalo-
sporins. A significant increase in consumption was found for
extended-spectrum cephalosporins, carbapenems, and flu-
oroquinolones from 2005 to 2010. By contrast, the
Figure 1. Annual consumption of six major groups of antimicrobial agents from 2005 to 2010. Note. Aminoglycosides include
amikacin and gentamicin; b-lactam-b-lactamase inhibitor combinations include piperacillinetazobactam; carbapenems
include imipenem, meropenem, and ertapenem; extended-spectrum cephalosporins include ceftriaxone, flomoxef, ceftazidime,
cefepime, and cefpirome; fluoroquinolones include ciprofloxacin, moxifloxacin, and levofloxacin.
Table 1 Correlation between each antibiotic and the
542 C.-K. Tan et al.consumption of aminoglycosides was significantly
decreased during the study period. Additionally, the use b-
lactam-b-lactamase inhibitor combinations and sulbactam
remains stable with time.
Trend of antibiotic resistance among A. baumannii
isolates
A total of 473 nonduplicate A. baumannii isolates causing
HCAIs were identified during the study period and tested for
susceptibility. Fig. 2 shows the trends of imipenem resis-
tance rate among A. baumannii isolates. The incidence of
HCAI caused by IRAB (p Z 0.032) was found to be signifi-
cantly increased with time. Additionally, we found that
only about 30e40% of A. baumannii isolates were suscep-
tible to amikacin, ceftazidime, and ciprofloxacin; however,
the incidence of HCAI caused by amikacin-, ceftazidime-, or0%
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Figure 2. Rates of imipenem-resistant Acinetobacter bau-
mannii (IRAB) among A. baumannii isolates causing health
care-associated infection (HCAI) and the incidence (per 1000
inpatient-days) of HCAI caused by IRAB.ciprofloxacin-resistant A. baumannii remained stable dur-
ing the study period.
Correlation between antibiotics consumption and
the incidence of HCAI caused by IRAB
The relationships between the incidence of HCAI caused by
IRAB and the annual consumption of various antibiotics are
shown in Table 1. A positive correlation between the in-
crease in the use of fluoroquinolones and carbapenems, and
the incidence of HCAI caused by IRAB was noted. By
contrast, we did not find any significant relationship be-
tween the use of extended-spectrum cephalosporins,
b-lactam-b-lactamase inhibitor combinations, sulbactam,incidence of health care-associated infection due to
imipenem-resistant Acinetobacter baumannii
Correlation
ra p*
Extended-spectrum cephalosporins 0.787 0.063
b-Lactam-b-lactamase inhibitor
combinations
0.636 0.174
Aminoglycosides 0.501 0.312
Sulbactam 0.798 0.057
Fluoroquinolones 0.819 0.046
Ciprofloxacin 0.721 0.106
Levofloxacin 0.333 0.667
Moxifloxacin 0.684 0.134
Carbapenems 0.833 0.039
Imipenem 0.646 0.166
Meropenem 0.487 0.327
Ertapenem 0.237 0.763
a r denotes Pearson’s correlation coefficient.
*Statistically significant association (marked in bold type;
p < 0.05).
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IRAB. However, there was no significant correlation be-
tween the consumption of each fluoroquinolone (including
ciprofloxacin, levofloxacin, and moxifloxacin) and carba-
penem (including ertapenem, meropenem, and imipenem)
and the incidence of HCAI caused by IRAB.
Discussion
This study evaluated the association between antibiotic
consumption and the incidence of HCAI caused by IRAB in a
hospital in southern Taiwan during a 6-year period. Overall,
the trend in consumption of most antibiotics, including
extended-spectrum cephalosporins, carbapenems, and flu-
oroquinolones, was significantly increased during the study
period. For carbapenems, in particular, and fluo-
roquinolones, the use of each antibiotic dramatically
increased by about 3.5-fold and 2-fold, respectively. On the
contrary, the consumption of aminoglycosides significantly
decreased during this period, which might be attributable
to the notable nephrotoxicity of these agents.
In this institution, HCAI caused by IRAB significantly
increased during the study period. By contrast, the inci-
dence of HCAI caused by amikacin-, ceftazidime-, and
ciprofloxacin-resistant A. baumannii remained stable. In
the past year of this study, more than half of A. baumannii
isolates were resistant to imipenem, and only less than 40%
of A. baumannii isolates remained susceptible to amikacin,
ceftazidime, and ciprofloxacin. Our findings are consistent
with those of a previous study conducted in a medical
center in northern Taiwan,18 which showed the high resis-
tance rate of A. baumannii isolates causing HCAI. All of the
above findings would suggest that the choices of antibiotics
are limited in this era of A. baumannii with in vitro high
antibiotic resistance. Novel antibiotics or combination
therapies should be considered when dealing with this
antibiotic-resistant pathogendA. baumannii.
In this study, we found that the increasing use of car-
bapenems was associated with the increasing incidence of
HCAIs caused by IRAB. This is consistent with the finding of
Lai et al18 and Hsu et al23 that there is a positive correlation
between the use of carbapenems and imipenem-resistant
Acinetobacter spp. However, while looking for the specific
association between ertapenem, imipenem, meropenem,
and the incidence of HCAI caused by IRAB, we did not find
any significant correlation. Although we demonstrated the
increasing use of total carbapenems and the incidence of
HCAI caused by IRAB in this study, further study is necessary
to determine the association between each carbapenem
and the incidence of HCAI caused by IRAB. Nevertheless,
our findings suggest that in the hospital where imipenem
resistance is endemic for A. baumannii isolates and the
prescription rate of broad-spectrum antibiotic agents is
high, caution in antibiotic use would play an important role
in managing high resistance rates.
In addition to carbapenems, we also found that the use
of fluoroquinolones was positively associated with the
incidence of HCAI caused by IRAB. In concordance with
carbapenems, the incidence of HCAI caused by IRAB
correlated only with the total consumption of fluo-
roquinolones, but not with any of the fluoroquinolones,
such as ciprofloxacin, levofloxacin, and moxifloxacin. This iscontrary to the studies carried out for Pseudomonas aeru-
ginosa, which showed that the associations between the
antibiotic resistance rate of bacteria and ciprofloxacin,
levofloxacin, or ciprofloxacin plus levofloxacin varied.23e25
The difference may be attributable to the different path-
ogens or study design used, so we still need more data to
confirm the specific role of each fluoroquinolone.
Currently, based on our findings, it may be suggested that
cautious use of fluoroquinolones is helpful in reducing HCAIs
caused by IRAB.
This study has several limitations. Although we found a
significant correlation between antibiotic use and the
incidence of HCAI caused by IRAB, the etiology behind the
emergence of drug-resistant bacteria in our hospital is
complicated, and selective pressure from the widespread
use of antibiotic agents might be only one of the causes.
The incidence of IRAB could have been affected by multiple
factors, such as infection control measures and hand hy-
giene, or operational changes in the hospital. In addition,
because this investigation is basically an epidemiological
surveillance study only, we did not analyze the impact of
the duration of exposure to antibiotics, or the clonal spread
of resistant bacteria on the trend of the incidence of HCAI
caused by IRAB. Finally, we did not use molecular methods
for identification of the A. baumannii complex, which
included at least three Acinetobacter genomic species: A.
baumannii, Acinetobacter pittii, and Acinetobacter noso-
comialis. Therefore, some misidentifications of bacterial
species can occur and further affect our analysis.
In conclusion, we found that the consumption of most of
the antibiotics, except aminoglycosides, was significantly
increased during this 6-year study in a Taiwanese hospital.
The increasing use of carbapenems and fluoroquinolones
was associated with the increasing incidence of HCAI
caused by IRAB.
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